View in EDS

Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.

Saved in:
Bibliographic Details
Title: Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
Authors: Brisson, Marc (AUTHOR), Kim, Jane J (AUTHOR), Canfell, Karen (AUTHOR), Drolet, Mélanie (AUTHOR), Gingras, Guillaume (AUTHOR), Burger, Emily A (AUTHOR), Martin, Dave (AUTHOR), Simms, Kate T (AUTHOR), Bénard, Élodie (AUTHOR), Boily, Marie-Claude (AUTHOR), Sy, Stephen (AUTHOR), Regan, Catherine (AUTHOR), Keane, Adam (AUTHOR), Caruana, Michael (AUTHOR), Nguyen, Diep T N (AUTHOR), Smith, Megan A (AUTHOR), Laprise, Jean-François (AUTHOR), Jit, Mark (AUTHOR), Alary, Michel (AUTHOR), Bray, Freddie (AUTHOR)
Source: Lancet. 2/22/2020, Vol. 395 Issue 10224, p575-590. 16p.
Subjects: Genital warts, Human papillomavirus vaccines, Cervical cancer, Low-income countries, Medical Research Council (Great Britain), United Nations Development Programme, Early detection of cancer, Comparative studies, Pilot projects, Biological models, Research, Immunization, Research methodology, Medical screening, Disease incidence, Evaluation research, Medical cooperation, Income, Papillomavirus diseases, Research funding, Cervix uteri tumors, Developing countries, Disease complications
Abstract: Background: The WHO Director-General has issued a call for action to eliminate cervical cancer as a public health problem. To help inform global efforts, we modelled potential human papillomavirus (HPV) vaccination and cervical screening scenarios in low-income and lower-middle-income countries (LMICs) to examine the feasibility and timing of elimination at different thresholds, and to estimate the number of cervical cancer cases averted on the path to elimination.Methods: The WHO Cervical Cancer Elimination Modelling Consortium (CCEMC), which consists of three independent transmission-dynamic models identified by WHO according to predefined criteria, projected reductions in cervical cancer incidence over time in 78 LMICs for three standardised base-case scenarios: girls-only vaccination; girls-only vaccination and once-lifetime screening; and girls-only vaccination and twice-lifetime screening. Girls were vaccinated at age 9 years (with a catch-up to age 14 years), assuming 90% coverage and 100% lifetime protection against HPV types 16, 18, 31, 33, 45, 52, and 58. Cervical screening involved HPV testing once or twice per lifetime at ages 35 years and 45 years, with uptake increasing from 45% (2023) to 90% (2045 onwards). The elimination thresholds examined were an average age-standardised cervical cancer incidence of four or fewer cases per 100 000 women-years and ten or fewer cases per 100 000 women-years, and an 85% or greater reduction in incidence. Sensitivity analyses were done, varying vaccination and screening strategies and assumptions. We summarised results using the median (range) of model predictions.Findings: Girls-only HPV vaccination was predicted to reduce the median age-standardised cervical cancer incidence in LMICs from 19·8 (range 19·4-19·8) to 2·1 (2·0-2·6) cases per 100 000 women-years over the next century (89·4% [86·2-90·1] reduction), and to avert 61·0 million (60·5-63·0) cases during this period. Adding twice-lifetime screening reduced the incidence to 0·7 (0·6-1·6) cases per 100 000 women-years (96·7% [91·3-96·7] reduction) and averted an extra 12·1 million (9·5-13·7) cases. Girls-only vaccination was predicted to result in elimination in 60% (58-65) of LMICs based on the threshold of four or fewer cases per 100 000 women-years, in 99% (89-100) of LMICs based on the threshold of ten or fewer cases per 100 000 women-years, and in 87% (37-99) of LMICs based on the 85% or greater reduction threshold. When adding twice-lifetime screening, 100% (71-100) of LMICs reached elimination for all three thresholds. In regions in which all countries can achieve cervical cancer elimination with girls-only vaccination, elimination could occur between 2059 and 2102, depending on the threshold and region. Introducing twice-lifetime screening accelerated elimination by 11-31 years. Long-term vaccine protection was required for elimination.Interpretation: Predictions were consistent across our three models and suggest that high HPV vaccination coverage of girls can lead to cervical cancer elimination in most LMICs by the end of the century. Screening with high uptake will expedite reductions and will be necessary to eliminate cervical cancer in countries with the highest burden.Funding: WHO, UNDP, UN Population Fund, UNICEF-WHO-World Bank Special Program of Research, Development and Research Training in Human Reproduction, Canadian Institute of Health Research, Fonds de recherche du Québec-Santé, Compute Canada, National Health and Medical Research Council Australia Centre for Research Excellence in Cervical Cancer Control. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 141960938
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Brisson%2C+Marc%22">Brisson, Marc</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kim%2C+Jane+J%22">Kim, Jane J</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Canfell%2C+Karen%22">Canfell, Karen</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Drolet%2C+Mélanie%22">Drolet, Mélanie</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gingras%2C+Guillaume%22">Gingras, Guillaume</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Burger%2C+Emily+A%22">Burger, Emily A</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Martin%2C+Dave%22">Martin, Dave</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Simms%2C+Kate+T%22">Simms, Kate T</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bénard%2C+Élodie%22">Bénard, Élodie</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Boily%2C+Marie-Claude%22">Boily, Marie-Claude</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sy%2C+Stephen%22">Sy, Stephen</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Regan%2C+Catherine%22">Regan, Catherine</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Keane%2C+Adam%22">Keane, Adam</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Caruana%2C+Michael%22">Caruana, Michael</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Nguyen%2C+Diep+T+N%22">Nguyen, Diep T N</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Smith%2C+Megan+A%22">Smith, Megan A</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Laprise%2C+Jean-François%22">Laprise, Jean-François</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Jit%2C+Mark%22">Jit, Mark</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Alary%2C+Michel%22">Alary, Michel</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bray%2C+Freddie%22">Bray, Freddie</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. 2/22/2020, Vol. 395 Issue 10224, p575-590. 16p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Genital+warts%22">Genital warts</searchLink><br /><searchLink fieldCode="DE" term="%22Human+papillomavirus+vaccines%22">Human papillomavirus vaccines</searchLink><br /><searchLink fieldCode="DE" term="%22Cervical+cancer%22">Cervical cancer</searchLink><br /><searchLink fieldCode="DE" term="%22Low-income+countries%22">Low-income countries</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+Research+Council+%28Great+Britain%29%22">Medical Research Council (Great Britain)</searchLink><br /><searchLink fieldCode="DE" term="%22United+Nations+Development+Programme%22">United Nations Development Programme</searchLink><br /><searchLink fieldCode="DE" term="%22Early+detection+of+cancer%22">Early detection of cancer</searchLink><br /><searchLink fieldCode="DE" term="%22Comparative+studies%22">Comparative studies</searchLink><br /><searchLink fieldCode="DE" term="%22Pilot+projects%22">Pilot projects</searchLink><br /><searchLink fieldCode="DE" term="%22Biological+models%22">Biological models</searchLink><br /><searchLink fieldCode="DE" term="%22Research%22">Research</searchLink><br /><searchLink fieldCode="DE" term="%22Immunization%22">Immunization</searchLink><br /><searchLink fieldCode="DE" term="%22Research+methodology%22">Research methodology</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+screening%22">Medical screening</searchLink><br /><searchLink fieldCode="DE" term="%22Disease+incidence%22">Disease incidence</searchLink><br /><searchLink fieldCode="DE" term="%22Evaluation+research%22">Evaluation research</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+cooperation%22">Medical cooperation</searchLink><br /><searchLink fieldCode="DE" term="%22Income%22">Income</searchLink><br /><searchLink fieldCode="DE" term="%22Papillomavirus+diseases%22">Papillomavirus diseases</searchLink><br /><searchLink fieldCode="DE" term="%22Research+funding%22">Research funding</searchLink><br /><searchLink fieldCode="DE" term="%22Cervix+uteri+tumors%22">Cervix uteri tumors</searchLink><br /><searchLink fieldCode="DE" term="%22Developing+countries%22">Developing countries</searchLink><br /><searchLink fieldCode="DE" term="%22Disease+complications%22">Disease complications</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Background: </bold>The WHO Director-General has issued a call for action to eliminate cervical cancer as a public health problem. To help inform global efforts, we modelled potential human papillomavirus (HPV) vaccination and cervical screening scenarios in low-income and lower-middle-income countries (LMICs) to examine the feasibility and timing of elimination at different thresholds, and to estimate the number of cervical cancer cases averted on the path to elimination.<bold>Methods: </bold>The WHO Cervical Cancer Elimination Modelling Consortium (CCEMC), which consists of three independent transmission-dynamic models identified by WHO according to predefined criteria, projected reductions in cervical cancer incidence over time in 78 LMICs for three standardised base-case scenarios: girls-only vaccination; girls-only vaccination and once-lifetime screening; and girls-only vaccination and twice-lifetime screening. Girls were vaccinated at age 9 years (with a catch-up to age 14 years), assuming 90% coverage and 100% lifetime protection against HPV types 16, 18, 31, 33, 45, 52, and 58. Cervical screening involved HPV testing once or twice per lifetime at ages 35 years and 45 years, with uptake increasing from 45% (2023) to 90% (2045 onwards). The elimination thresholds examined were an average age-standardised cervical cancer incidence of four or fewer cases per 100 000 women-years and ten or fewer cases per 100 000 women-years, and an 85% or greater reduction in incidence. Sensitivity analyses were done, varying vaccination and screening strategies and assumptions. We summarised results using the median (range) of model predictions.<bold>Findings: </bold>Girls-only HPV vaccination was predicted to reduce the median age-standardised cervical cancer incidence in LMICs from 19·8 (range 19·4-19·8) to 2·1 (2·0-2·6) cases per 100 000 women-years over the next century (89·4% [86·2-90·1] reduction), and to avert 61·0 million (60·5-63·0) cases during this period. Adding twice-lifetime screening reduced the incidence to 0·7 (0·6-1·6) cases per 100 000 women-years (96·7% [91·3-96·7] reduction) and averted an extra 12·1 million (9·5-13·7) cases. Girls-only vaccination was predicted to result in elimination in 60% (58-65) of LMICs based on the threshold of four or fewer cases per 100 000 women-years, in 99% (89-100) of LMICs based on the threshold of ten or fewer cases per 100 000 women-years, and in 87% (37-99) of LMICs based on the 85% or greater reduction threshold. When adding twice-lifetime screening, 100% (71-100) of LMICs reached elimination for all three thresholds. In regions in which all countries can achieve cervical cancer elimination with girls-only vaccination, elimination could occur between 2059 and 2102, depending on the threshold and region. Introducing twice-lifetime screening accelerated elimination by 11-31 years. Long-term vaccine protection was required for elimination.<bold>Interpretation: </bold>Predictions were consistent across our three models and suggest that high HPV vaccination coverage of girls can lead to cervical cancer elimination in most LMICs by the end of the century. Screening with high uptake will expedite reductions and will be necessary to eliminate cervical cancer in countries with the highest burden.<bold>Funding: </bold>WHO, UNDP, UN Population Fund, UNICEF-WHO-World Bank Special Program of Research, Development and Research Training in Human Reproduction, Canadian Institute of Health Research, Fonds de recherche du Québec-Santé, Compute Canada, National Health and Medical Research Council Australia Centre for Research Excellence in Cervical Cancer Control. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=141960938
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(20)30068-4
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 16
        StartPage: 575
    Subjects:
      – SubjectFull: Genital warts
        Type: general
      – SubjectFull: Human papillomavirus vaccines
        Type: general
      – SubjectFull: Cervical cancer
        Type: general
      – SubjectFull: Low-income countries
        Type: general
      – SubjectFull: Medical Research Council (Great Britain)
        Type: general
      – SubjectFull: United Nations Development Programme
        Type: general
      – SubjectFull: Early detection of cancer
        Type: general
      – SubjectFull: Comparative studies
        Type: general
      – SubjectFull: Pilot projects
        Type: general
      – SubjectFull: Biological models
        Type: general
      – SubjectFull: Research
        Type: general
      – SubjectFull: Immunization
        Type: general
      – SubjectFull: Research methodology
        Type: general
      – SubjectFull: Medical screening
        Type: general
      – SubjectFull: Disease incidence
        Type: general
      – SubjectFull: Evaluation research
        Type: general
      – SubjectFull: Medical cooperation
        Type: general
      – SubjectFull: Income
        Type: general
      – SubjectFull: Papillomavirus diseases
        Type: general
      – SubjectFull: Research funding
        Type: general
      – SubjectFull: Cervix uteri tumors
        Type: general
      – SubjectFull: Developing countries
        Type: general
      – SubjectFull: Disease complications
        Type: general
    Titles:
      – TitleFull: Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Brisson, Marc
      – PersonEntity:
          Name:
            NameFull: Kim, Jane J
      – PersonEntity:
          Name:
            NameFull: Canfell, Karen
      – PersonEntity:
          Name:
            NameFull: Drolet, Mélanie
      – PersonEntity:
          Name:
            NameFull: Gingras, Guillaume
      – PersonEntity:
          Name:
            NameFull: Burger, Emily A
      – PersonEntity:
          Name:
            NameFull: Martin, Dave
      – PersonEntity:
          Name:
            NameFull: Simms, Kate T
      – PersonEntity:
          Name:
            NameFull: Bénard, Élodie
      – PersonEntity:
          Name:
            NameFull: Boily, Marie-Claude
      – PersonEntity:
          Name:
            NameFull: Sy, Stephen
      – PersonEntity:
          Name:
            NameFull: Regan, Catherine
      – PersonEntity:
          Name:
            NameFull: Keane, Adam
      – PersonEntity:
          Name:
            NameFull: Caruana, Michael
      – PersonEntity:
          Name:
            NameFull: Nguyen, Diep T N
      – PersonEntity:
          Name:
            NameFull: Smith, Megan A
      – PersonEntity:
          Name:
            NameFull: Laprise, Jean-François
      – PersonEntity:
          Name:
            NameFull: Jit, Mark
      – PersonEntity:
          Name:
            NameFull: Alary, Michel
      – PersonEntity:
          Name:
            NameFull: Bray, Freddie
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 22
              M: 02
              Text: 2/22/2020
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 395
            – Type: issue
              Value: 10224
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1